A novel biological assay to detect the active form of TGF-β in urine to monitor renal allograft rejection  by Rogier, Edith et al.
Kidney International, Vol. 68 (2005), pp. 1875–1883
TECHNICAL NOTE
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A novel biological assay to detect the active form of TGF-b in
urine to monitor renal allograft rejection.
Background. Transforming growth factor-b (TGF-b) plays
an important role in renal fibrosis. Measurement of the concen-
tration of the active form of TGF-b particularly in urine may
help our understanding of the mechanism of chronic allograft
nephropathy and could be used as a diagnostic tool. However,
TGF-b release and activation are complex and, consequently,
there is currently no accurate way to measure TGF-b activity.
Methods. TGF-b–sensitive BL41 cells were stably transfected
with a reporter plasmid harboring a synthetic TGF-b–inducible
DNA sequence upstream from the luciferase gene. Cells were
incubated with urine samples from normal donors or trans-
planted recipients with or without patent nephropathy, and the
active form of TGF-b was determined as luciferase activity.
Results. We have established a cell line which expresses
luciferase activity in response to active TGF-b in a dose-
dependent manner. Moreover, the use of a histone deacetylase
inhibitor greatly increased sensitivity to TGF-b and also stabi-
lized luciferase inductibility. This test is highly specific to active
TGF-b . Detectable levels of TGF-b were found in urine from
patients with renal dysfunction due to acute or chronic renal al-
lograft rejection (P < 0.001), but not in that from patients with
stable, correctly functional kidneys.
Conclusion. We describe a highly sensitive and specific assay
for active TGF-b . We also show that, in cases of renal allograft,
TGF-b expression is highly and significantly correlated with
acute or chronic rejections.
Numerous recent studies have investigated the role of
transforming growth factor-b (TGF-b) in renal transplan-
tation and strong evidence support the involvement of
TGF-b in renal fibrosis [1]. TGF-b is a cytokine with
profibrogenic but also anti-inflammatory and immuno-
suppressive effects [2]. In cases of renal allograft, on one
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hand it may favor fibrosis, leading to a renal dysfunc-
tion, and on the other hand it could reduce the allo-
genic immune response [3]. Indeed, results from differ-
ent experimental rodent models of renal transplantation
suggest that TGF-b has a causative role in the matrix
expansion that occurs in chronic allograft nephropathy
[4–6]. Moreover, TGF-b expression has been shown to
be up-regulated in renal biopsies of patients with chronic
allograft nephropathy (CAN) [7, 8].
This physiopathologic relevance of TGF-b in fibro-
genic kidney disease and its increased expression as as-
sessed by immunochemistry or by assaying mRNA levels
in clinical studies suggest that measurement of TGF-b
would be valuable: it could improve our knowledge of
the mechanism of chronic nephropathy and be used as a
diagnostic tool [8].
TGF-b is synthesized as a proform and, after pro-
cessing, the N-terminal domain, also called latent-
associated protein (LAP), associates noncovalently to the
C-terminal domain, which is the mature bioactive TGF-
b . Latent TGF-b is thus released as an inactive precursor
in a complex bound to LAP [9, 10]. Activation of the com-
plex occurs by different mechanisms and only the active
form of TGF-b is physiologically relevant. TGF-b release
and activation are, thus, complex and as a consequence,
no accurate measurement technique is available to dis-
criminate between the latent and active forms. Indeed,
the antibodies used in immunochemical studies to deter-
mine TGF-b levels do not discriminate between the in-
active and the active forms. Likewise, measuring mRNA
levels indicate that increased levels of TGF-b have been
produced, but are not informative about the expression
of the active form. Some bioassays for detecting active
TGF-b are based on its antiproliferative effect on var-
ious cell lines. However, these assays are not very sen-
sitive and required 2 days to complete. A test has been
developed using the extracellular domain of the type II
TGF-b receptor as the capture reagent for the active form
in enzyme-linked immunosorbent assay (ELISA). This
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assay has yielded to paradoxic data concerning the pres-
ence of TGF-b in normal human plasma [11]; the results
are difficult to interpret because it is unclear which TGF-
b complexes bind to the receptor in vitro.
TGF-b binding to TGF-b receptor II triggers het-
eromerization and transphosphorylation of TGF-b
receptor I (TbRI). Phosphorylation of the cytoplasmic
domain of TbRI promotes its kinase activation, thereby
allowing propagation of the signal to downstream com-
ponents [12]. Thus, upon ligand-induced activation of the
TGF-b receptors, the receptor-regulated Smads (Smad2
and Smad3) interact directly with TbRI and are phos-
phorylated. This phosphorylation event results in their
association with the common mediator, Smad4. The com-
plexes translocate to the nucleus, where they induce a
large number of target genes by binding directly to DNA
or by association with DNA binding proteins [13]. The
Smad3/Smad4 complex binds to a specific Smad binding
element (SBE) sequence, which is present in the promot-
ers of TGF-b target genes [14].
Taking advantage of the ability of activated Smad3 to
bind this DNA sequence [14], we developed an assay to
quantify the concentration of the active form of TGF-b
based on activation of a synthetic SBE sequence placed
upstream of the luciferase reporter gene and stably intro-
duced in BL41 cells. Since this assay is based on a biolog-
ical activity, it detects the active form of TGF-b , which is
the only form capable to bind and activate the receptor.
Smad-mediated signals are regulated by several
downstream effectors and, in particular, by proteins
involved in chromatin modification [15]. Inhibition of
histone deacetylase (HDAC) leads to a large increase
in the Smad-mediated signal, making these cells highly
and specifically sensitive to TGF-b . We used this phe-
nomenon to develop an assay for active TGF-b measure-
ment in urine from transplanted patients. We here show
that expression of the active form of TGF-b is signif-
icantly associated with biopsy-proven acute or chronic
rejection episode.
METHODS
Cell line and materials
The Madin-Darby canine kidney (MDCK) cells were
maintained in Dulbecco’s modified medium containing
10% fetal calf serum. The Burkitt’s lymphoma cell line
BL41 was maintained in RPMI medium containing 10%
fetal calf serum. The (CAGA) 9-MLP-luc reporter vec-
tor harboring 9 SBE sites and a MLP minimal promoter
upstream from the luciferase gene was a generous gift
from Dr. J.M. Gautier [14]. pMEP4 hygro plasmid and hy-
gromycin B were from Invitrogen (Carlsbad, CA, USA).
Recombinant TGF-b 1 and trichostatin A (TSA) were
from Sigma (St. Louis, MO, USA) and Calbiochem (San
Diego, CA, USA), respectively. Epidermal growth factor
(EGF), platelet-derived growth factor (homodimer of 2
B chains; PDGF-BB), interleukin 2 (IL-2), and 3 (IL-3)
were from PeproTech (London, UK). Human recombi-
nant IFNa2b (specific activity 2.04 × 108 U/mg) was from
Schering-Plough (Kenilworth, NJ, USA), and human re-
combinant IFNc (specific activity 2 × 107 U/mg) was from
Roussel Uclaf (Romainville, France).
Monoclonal neutralizing antibody directed against the
b1, b2, and b3 isoforms of TGF was from R&D Sys-
tems (Minneapolis, MN, USA). Anti-TGF-b3 antibodies
(sc82) were from Santa Cruz (Santa Cruz, CA, USA).
The TGF-b1 Emax Immunoassay system was from
Promega (Madison, WI, USA), the human TGF-b1 im-
munoassay Quantikine was from R&D Systems. PIIINP
RIA was purchased from Orion Diagnostica (Espoo,
Finland).
Cell transfection and luciferase assays
For transient transfection, the (CAGA)9-luc vec-
tor was introduced in BL41 cells by electroporation
(960 lF, 240 V in a BioRad apparatus; BioRad, Hercules,
CA, USA) and in MDCK cells using the lipofectamine
method (Invitrogen) as previously described [16]. For
stable transfection, BL41 were cotransfected with the
(CAGA)9-luc vector together with the pMEP4 hygro
(ratio 20/1) vector. Stable transfectants were selected
by incubating the cells with 0.5 mg/mL hygromycin for
3 weeks. Stable clonal transfectants were isolated from
hygromycin-resistant cells using the limiting dilution
technique. Each clone was treated for 18 hours with in-
creasing doses of TGF-b and the TGF-b response was
estimated by measuring luciferase activity in a multiwell
plate luminometer (Berthold) using a luciferase assay ac-
cording to the manufacturer’s instructions (Promega).
The positive clones were then expanded and frozen
in liquid nitrogen. Cell thawing was considered as
passage 1.
Urine samples
Urine from healthy people, transplanted patients with
stable renal function, and patients with renal dysfunction
having a biopsy proven chronic or acute rejection was
studied. Fresh urine was collected and centrifuged, and
supernatants were rapidly frozen for storage.
Determination of TGF-b levels in urine
Two hundred and fifty lL of urine was added to
250 lL of RPMI medium containing 10% fetal calf serum,
and 500 lL of the cell suspension (106 cells) was then
added in the presence or absence of 200 nmol/L TSA.
The samples were incubated for 18 hours and luciferase
activity was determined. TGF-b concentrations were cal-
culated from the luciferase activity using a standard curve
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obtained for each experiment, with known amounts of
TGF-b dissolved in urine from normal donors.
To test the specificity of the assay, 250 lL of urine pos-
itive for TGF-b was incubated for 1 hour at 4◦C with or
without 0.5 lg of neutralizing anti–TGF-b antibodies and
TGF-b activity was then determined.
Immunohistochemistry
Renal biopsies, fixed in 4% paraformaldehyde, were
embedded in paraffin. Deparaffinized sections were
treated with 3% hydrogen peroxide to quench endoge-
nous peroxidase activity, incubated for 30 minutes with
rabbit polyclonal anti–TGF-b antibodies at dilution 1/200
in TBS and then with HRP-labeled secondary antibod-
ies (Dako Envision Systems, Carpinteria, CA, USA) for
another 30 minutes. Immunoperoxidase staining was car-
ried out with diaminobenzidine. Negative controls were
incubated in TBS instead of the primary antibody.
RESULTS
Establishment of a cell line stably expressing
TGF-b–inducible luciferase and increasing activity
by trichostatin A treatment
We first determined the best appropriated cell type to
quantify TGF-b . For this, epithelial or B cells were tran-
siently transfected with the reporter plasmid (CAGA)9-
MLP-Luc, and treated with different amounts of TGF-b .
As expected, TGF-b induced luciferase activity in both
cell lines (Fig. 1A). However, the Burkitt’s lymphoma B
cell line (BL41) responded at doses of TGF-b less than
the epithelial MDCK cell line. Moreover, the basal level
of luciferase activity was also lower in BL41 cells than in
MDCK cells, suggesting that MDCK could produce some
TGF-b . Thus, because of its high sensitivity and because
it did not produce endogenous TGF-b , the Burkitt’s lym-
phoma cell line BL41 was used to develop an assay to test
the active form of TGF-b . Five independent clones stably
transfected with the reporter plasmid (CAGA)9-MLP-
Luc, were responsive to TGF-b in a dose-dependent man-
ner, leading to an increase in luciferase activity in the
cell lysates (Fig. 1B). One clone, BL/CL14, exhibiting a
high responsiveness to TGF-b , was selected for the sub-
sequent work in this study.
Evidence has been accumulated in support of a key
role of chromatin modification in gene activation [17].
Indeed, the efficacy of binding of transcription factors is
not solely determined by specific DNA sequences, but
also by epigenetic modifications of the chromatin. Con-
cerning TGF-b signaling, it has been established that CBP
and p300 proteins mediate activation of several TGF-b
target genes by placing Smad2 or Smad3 in proximity
of the general transcription machinery and by modify-
ing the chromatin structure through histone acetylation
[18, 19]. Several corepressors of Smad transcription (Ski,
Sno, or TGIF) provoke Smad transcriptional repression
by enhancing histone deacetylation [20, 21]. We thus used
the histone deacetylase inhibitor (HDAC), trichostatin A
(TSA), to determine whether modifying chromatin struc-
ture increases TGF-b–mediated Smad-dependent tran-
scription. BL/CL14 cells (5th passage) were treated with
TGF-b in the presence and in the absence of TSA. Treat-
ment of BL/CL14 cells with TSA alone did not induce
luciferase activity (Fig. 1C). However, TSA considerably
increased the sensitivity of these cells to TGF-b . This was
particularly striking when low doses of TGF-b were used.
Indeed, a concentration of TGF-b as low as 7 pg/mL was
able to induce luciferase activity significantly in the pres-
ence of TSA (Fig. 1C). The same results were obtained
when another clone was studied (BL/CL17) (Fig. 1D),
suggesting that this effect of TSA is not due to the inte-
gration site of the plasmid, but is directly related to an
increase in Smad3 activation.
Trichostatin A (TSA) stabilizes TGF-b–mediated
inducibility of the cells
A gradual loss of inducibility with time has been ob-
served with various inducible promoters stably integrated
into the genome. It has been shown that the repressed ac-
tivity of the integrated promoters was due, at least partly,
to changes in acetylation/deacetylation and nucleosome-
dependent repression of the promoter [22]. To examine
the stability of our cell clone and the inducibility with
duration of the culture, we compared the luciferase ac-
tivities of cells treated with TGF-b with or without TSA
after 4, 5, or 6 passages (Fig. 2A) and 11, 12 and 13 pas-
sages (Fig. 2B). Luciferase inducibility by TGF-b in the
absence of TSA was substantially lower after 12 passages
than after 5. However, when 200 nmol/L TSA was added
to the BL/CL14 cells together with TGF-b , luciferase ex-
pression was still induced, and cells retained the ability
to respond detectably to as little as 15 pg/mL of TGF-b
after 12 passages. This is consistent with histone acetyla-
tion being necessary for Smad accessibility and binding
to DNA. This result underlines the importance of TSA
not only to increase the sensitivity of the clone to TGF-b
but also to the maintaining of inducibility of the cells.
Specificity of the assay
To our knowledge, Smad activation is restricted to pro-
teins of the TGF-b family. To confirm that activation
of other pathways would not activate a SBE sequence,
BL/CL14 cells were treated with either PDGF-BB
(10 ng/mL), EGF (10 ng/mL), IFNa (1000 U/mL), IFNc
(1000 U/mL), IL2 (1 ng/mL), or IL3 (1 ng/mL) for
18 hours in the presence or in the absence of TSA. In
contrast to TGF-b , none of these growth factors or cy-
tokines were able to induce luciferase activity (data not
shown).
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Fig. 1. TGF-b–induced luciferase activity of different clones stably expressing (CAGA)9-luc. Effect of trichostatin A (A) BL41 or MDCK cells
were transfected with (CAGA)9-luc and treated with various doses of TGF-b for 18 hours. Luciferase activity was then measured. (B) BL41 cells
were cotransfected with (CAGA)9-luc and pMEP4-hygro, selected for hygromycin resistance, and cloned as described in Methods. Cells were
treated for 18 hours with various doses of TGF-b and luciferase activity was measured. (C) BL/CL14 cells were treated for 18 hours with various
amounts of TGF-b in the presence or in the absence of 200 nmol/L TSA. Luciferase activity was then measured. (D) BL/CL17 cells were treated
for 18 hours with various amounts of TGF-b in the presence or in the absence of 200 nmol/L TSA. Luciferase activity was then measured.
Assaying TGF-b in urine
The high sensitivity of BL/CL14 cells to TGF-b
prompted us to determine whether this cell line could be
used to detect TGF-b in the urine of patients. To look for
a possible interference between TGF-b activity and urine
constituents we first compared TGF-b activity in medium
versus urine. TGF-b was diluted in RPMI medium or
in urine of healthy donor in the presence of TSA. Cells
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Fig. 2. Stability of the clone BL/CL14 BL/CL14 cells, cultured for 4, 5,
and 6 passages (A) or 11, 12, and 13 passages (B) were treated for 18
hours with various amounts of TGF-b in the presence or in the absence
of 200 nmol/L TSA. Luciferase activity was then measured. The values
are from one representative experiment.
were added to the different dilutions of TGF-b and incu-
bated for 18 hours before determining luciferase activity
(Fig. 3A). TGF-b activity values obtained for urine were
slightly higher than those for medium, indicating that
TGF-b is at least as active in urine as in culture medium.
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Fig. 3. TGF-b activity in urine. (A) TGF-b was serially diluted in urine
or in RPMI medium. BL/CL14 cells were added to the dilutions in
the presence of 200 nmol/L TSA. Luciferase activity was determined
after an 18-hour incubation. (B) TGF-b was diluted in urine samples of
various pH and cells were added as in (A).
Because the pH of urine differs between donors and is
acidic in many cases, we determined whether TGF-b ac-
tivity could be affected by pH. For this, serial dilutions of
TGB-b were realized in urine from normal donors of var-
ious pH. pH did not modify TGF-b–mediated luciferase
activity (Fig. 3B). Similarly, TGF-b–mediated luciferase
activity was not affected by urine osmolality (not shown).
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Table 1. Urine from renal transplanted patients with renal
dysfunction justifying the need for a histologic examination of their
kidney was collected just before renal biopsy and frozen until
determination of TGF-b activity
TGF-b positive TGF-b negative
(N = 17) (N = 48)
Graft rejection 13a 3
Absence of rejection 4 45
aP < 0.00001.
In vitro, acid pH (pH 2) can activate latent TGF-b by
disruption of the interaction between LAP and the ac-
tive form of TGF-b [10]. Moreover, significant levels of
latent TGF-b are found in calf serum, included in the cul-
ture medium. We tested whether TGF-b activity repre-
sented secreted active TGF-b or latent TGF-b activated
in urine by acid pH: we studied activation of latent TGF-
b in fetal calf serum after incubation with 50 urine sam-
ples of various pH between 5 and 7, from normal donors.
Luciferase activity was never detected, strongly suggest-
ing that luciferase activation is specific to active TGF-b
and is not a consequence of activation of latent TGF-b
by urine acidity (not shown).
Correlation between active TGF-b concentration in urine
of transplanted patients and graft rejection
Having established that TGF-b remains active when
diluted in urine, we investigated whether active TGF-b
detected in urine could be of value for monitoring renal
dysfunction. We first tested urine from more than 100
healthy donors aged between 20 and 60 years old. All of
these samples were negative for TGF-b . We then tested
urine from 60 renal transplant patients of diverse age,
duration of transplantation, type of immunosuppression,
and both sexes; all had stable renal function and no clini-
cal evidence of acute or chronic dysfunction. TGF-b was
not detected in the urine of any of these patients (not
shown).
We then investigated 66 patients who underwent re-
nal allograft transplantation and subsequently suffered
renal dysfunction. These patients also underwent renal
biopsy just after urine collection. TGF-b was detected in
the urines of 17 patients. TGF-b levels varied from 20 to
100 pg/mL for 11 patients, and 6 patients exhibited a con-
centration of TGF-b equal or higher than 250 pg/mL in
their urine (Table 1). We also tested whether TGF-b con-
centration varied with time: on the 3 patients tested, we
found that TGF-b levels were comparable in urine of the
same patient at different periods of time, ranging from 1
to 8 days (not shown). All of these patients scoring posi-
tive had an active nephropathy, including acute rejection,
chronic rejection, acute tubular necrosis, or thrombotic
microangiopathy. Interestingly, the presence of TGF-b in
urine was highly correlated with biopsy proven renal graft
rejection. Indeed, 80% of patients with acute or chronic
graft rejection had detectable TGF-b in their urine. Fur-
thermore, TGF-b expression was never detected in urine
of any patient without patent nephropathy.
Urines positive for TGF-b were also analyzed with
another cell clone stably transfected with the CAGA-
Luc reporter plasmid. The same levels of active TGF-b
were detected when BL/CL17 cells were used (data not
shown), showing the reproducibility of the assay. To test
the specificity of our assay, all the positive samples were
incubated with neutralizing antibodies directed against
the TGF-b1, b2, and b3 isoforms. In all cases, this treat-
ment reversed the positivity of the test, indicating that
the luciferase activity was in all cases due to the presence
of active TGF-b (Table 2). The presence of active TGF-b
was not correlated with the pH of the urine, indicating
that TGF-b was secreted in an active form and not as a
latent form subsequently activated by the acidity of the
urine (Table 2). Moreover, presence of TGF-b in urine
was not correlated with age, date of transplantation, or
with the initial disease of these patients (Table 2).
Because TGF-b in urine could arise from glomerular
filtration as proteinuria or from a local production and
then not correlated to proteinuria, we also investigated
whether a relationship exists between active TGF-b lev-
els in urine and proteinuria. We first investigated pro-
teinuria levels in patients having a negative detection of
have urinary active TGF-b . The range of proteinuria var-
ied from 0 to 1.4 g/day, with a mean value of 0.7. Most
of the patients positive for active TGF-b in urine ex-
hibited proteinuria levels ranging from 0.2 to 3.3 g/day,
with a mean value of 1.2, which is consistent with an ac-
tive nephropathy. However, no correlation could be es-
tablished between the degree of proteinuria and TGF-b
levels (not shown), which suggests that TGF-b has been
secreted in this active form and is not a consequence of
its activation in urine by released factors.
In order to correlate the levels of TGF-b obtained
using our assay with other assays used to detect active
TGF-b in different fluids, the same positive or nega-
tive samples were analyzed with known assays (i.e., the
TGF-b1 immunoassay Quantikine and the TGF-b1
Emax Immunoassay system) according to the manufac-
turer’s instructions. All samples negative in our assay
were also negative when tested with both commercial
assays (not shown). Concerning the samples positive for
TGF-b , some TGF-b could be detected with the TGF-
b1 Emax Immunoassay system or TGF-b1 immunoassay
Quantikine, but only when these samples were highly pos-
itive in our assay (Fig. 4), suggesting a higher sensitivity
of our test.
Clinical correlations
TGF-b expression has been correlated to chronic re-
jection [23]. Our study suggests that secretion of ac-
tive TGF-b in urine was also observed during acute
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Table 2. Positivity of the assay is not correlated with age, primary nephropathy, type of rejection, or urine pH of patients, and is specific to TGF-b
TGF-b levels
Age Transplantation Type of Urine without with antibodies
Patient years months Primary nephropathy rejection Urine pH antibodies pg/mL
1 40 1 Chronic pyelonephritis Acute 5.5 4000 28
2 56 20 IgA Chronic 5.8 250 <10
3 43 27 polykystosis Acute 6.7 60 <10
4 49 1 polykystosis Acute 6.1 500 <10
5 35 13 HTA CAN 7.2 40 <10
6 61 1 Diabetes Acute 6.2 72 <10
7 74 204 HTA CAN 5.9 40 <10
8 41 1 IgA CAN 5.2 50 <10
9 34 2 HTA Acute 7,5 500 <10
10 48 1 HTA CAN 7 80 <10
11 54 4 Alport Acute 6 250 <10
12 56 24 IgA Acute 6 250 <10
13 57 113 polykystosis Chronic 5,5 25 <10
14 74 148 ND Chronic 6,7 93 <10
15 54 250 ND Chronic 7 60 <10
16 47 1 Amylosis Acute 5,7 78 <10
17 44 51 Vesicoureteral Reflux Chronic ND 140 <10
Abbreviations are: CAN, chronic allograft nephropathy; ND, not determinated. Urine from positive patients was incubated with anti–TGF-b antibodies directed
against the b1, b2, and b3 isoforms as described in Methods and TGF-b was assayed.
Our assay
Emax Immunoassay
Quantikine
600
400
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0
1 2 3 4 5 6 7
TG
F-
β, 
pg
/m
L
Patient number
Fig. 4. Determination of TGF-b levels with different assays. TGF-b
levels from urines of 7 patients were determined using our assay, the
TGF-b1 Quantikine, or the TGF-b1 Emax immunoassay. Results are
representative of one experiment performed 3 times.
rejections. To determine whether TGF-b is locally ex-
pressed in kidney transplants during acute or chronic re-
jection we performed immunohistochemistry studies on
different renal biopsies using an anti–TGF-b antibody,
which recognizes its 3 isoforms. Examination of these re-
nal allograft biopsies obtained from 3 patients with acute
rejection and 3 patients with chronic rejection revealed
a specific TGF-b immunostaining in the tubular cells of
these patients, whatever the type of rejection, showing
that TGF-b expression was easily detectable in kidney
biopsies from chronic but also acute rejections (Fig. 5).
DISCUSSION
Renal transplantation is an important treatment for
patients with end-stage renal disease. However, issue of
this therapy is still hampered by the occurrence of renal
dysfunction responsible of graft loss. Although the use of
new combinations of immunosuppressive drugs have de-
creased the incidence of acute graft rejections to 10% to
20% of renal transplants, chronic rejection is still respon-
sible for the loss of 5% of grafts per year following trans-
plantation. In most cases, the fibrosis of kidney or vessels
is the main factor involved in chronic renal dysfunction.
Fibrosis is characterized by the progressive accumulation
of extracellular matrix material, and numerous studies
have demonstrated that TGF-b is a key mediator of this
fibrotic process. The potential profibrotic actions of TGF-
b include stimulation of matrix synthesis and inhibition
of matrix degradation. There is currently no satisfactory
technique for monitoring or detection of extracellular
matrix deposition. Monitoring of transplant rejection is
based on repeated transplant biopsies, which appeared
as a gold standard. This procedure is invasive, with side
effects going from minor urine bleeding to death; it is
not necessarily representative and cannot identify mech-
anisms involved in fibrosis. Furthermore, this procedure
cannot be repeated many times during the life of the
transplant. Thus, improvements in monitoring patients to
early detect acute or chronic graft rejection are required
to be able to adapt treatments.
Concerning TGF-b , most of the tests performed in the
blood have been unsatisfactory mainly because rejection
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Fig. 5. TGF-b immunohistochemistry staining of renal allograft biop-
sies. Renal biopsies were immunostained with anti–TGF-b antibod-
ies and representative results are shown. (A) Negative control without
anti–TGF-b antibody, (B) chronic rejection, (C) acute rejection.
is a local (i.e., in the graft) event rather than a general one
and cannot be used for detection of chronic or acute renal
graft rejection. Testing for TGF-b in urine could indicate
local release in the kidney, but such tests have previously
been disappointing for a long time possibly because very
small amounts of this cytokine are released in the urine
and many tests were not enough sensitive.
We describe an assay for detection of TGF-b levels that
is sufficiently sensitive to detect very low concentrations
of this cytokine, allowing detection in urine. More impor-
tantly, this assay is based on a biological activity and thus
only detects the active form of the molecule. The conver-
sion of latent to active TGF-b provides a pivotal mecha-
nism for the regulation of its biological activity, and the
physiologic significance of its expression thus obviously
depends on the availability of the biologically active form.
Our assay thus gives pertinent results, as only the form
mediating the matrix expansion that occurs in allograft
nephropathy is measured.
The specificity of our assay is based on activation of
the Smad pathway, particularly Smad3, by TGF-b . In
agreement with the fact that Smad activation is restricted
to TGF-b family members, our observation that vari-
ous growth factors or cytokines did not induce luciferase
activity points out that this induction was restricted
to the presence of active TGF-b . Moreover, in accor-
dance, luciferase activity was completely abolished when
urines containing TGF-b were incubated with the cells in
the presence of neutralizing antibodies directed against
TGF-b isoforms, demonstrating the specificity of this
assay.
It is known that chromatin environment plays a critical
role in the regulation of gene expression, and inducible
promoters progressively lose their inducibility although
they are still stably integrated into the genome [22]. We
show here that the deacetylase inhibitor TSA not only
considerably increased the sensitivity of the cells to TGF-
b but also maintained Smad-mediated inducibility of the
cells. This is of particular interest because attempts to use
this type of approach to develop tests to titrate cytokines
have been so far disappointing because of the progressive
loss of inducibility of synthetic promoters.
Sensitive assays for TGF-b in its active form could be
very valuable for detection and subsequent monitoring
of kidney transplant rejection. Indeed, we found a very
strong correlation between renal graft rejection and the
presence of TGF-b in urine. Because this detection was
realized in urine, it is not invasive and could be easily
and routinely performed. Compared to commercial as-
says our test appeared to be more sensitive: this could be
due to the fact that the commercials assays detect only
the TGF-b1 isoform, while our assay, based on binding
to the receptor and activation of TGF-b signaling, de-
tects the 3 TGF-b isoforms. Furthermore, immunohisto-
chemistry studies performed on renal biopsies revealed
a close correlation between the presence of TGF-b in
the transplant kidney and active TGF-b in their urine.
Interestingly, TGF-b was found in biopsies from patients
presenting an acute rejection, which is in accordance with
a previous report involving TGF-b signaling in acute re-
jection [24].
This test could be used as a diagnostic tool, and more in-
terestingly, would be helpful to follow the effects of modi-
fications of immunosuppressive protocols used to prevent
or to treat acute or chronic graft rejection episodes as well
as nonimmunosuppressive therapies.
A recent study has shown that the urinary amino-
terminal propeptide of type III procollagen (PIIINP) re-
flects the ongoing fibrotic process in the kidney [25], and a
correlation was found between urinary PIIINP and TGF-
b levels. We could not find such a relationship using our
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assay (not shown). This could be due to the fact that this
correlation has been established with an assay which, in
contrast to ours, does not discriminate between active
and latent TGF-b [26]. Another possibility could be that
our test, which has a higher sensitivity, can detect TGF-
b in urine before the presence of important deposit of
prefibrotic matrix.
TGF-b production has been implicated in the develop-
ment of renal fibrosis associated with various kidney dis-
eases, including diabetes [27] and nephronophthisis [28],
the most common genetic cause of chronic renal failure
in children. We are investigating whether these diseases
are associated with the presence of active TGF-b in urine.
There is also growing evidence that TGF-b production by
cancer cells is involved in tumor invasion [29]. Our assay
would allow detection of TGF-b in urine of patients with
renal cancer and therefore be used to correlate the levels
of active TGF-b in urine and tumor aggression, as well
as to follow the impact of therapies on tumor eradica-
tion. Furthermore, TGF-b is now considered as a potent
fibrotic agent in many tissues [3, 30]. Determination of ac-
tive TGF-b levels in different fluids could help to monitor
fibrosis development in different pathologies.
CONCLUSION
We demonstrate that active TGF-b is present in the
urine of patients with nephropathy. We have devel-
oped an assay suitable for detecting renal graft rejec-
tion episodes, and which is very promising for monitoring
most forms of kidney disease involving interstitial fibrosis
and inflammation.
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